74 related articles for article (PubMed ID: 25831835)
1. [Ara-C].
Onozawa M; Teshima T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():623-7. PubMed ID: 25831835
[No Abstract] [Full Text] [Related]
2. Clinical pharmacology of intermediate and low-dose cytosine arabinoside (ara-C) therapy in patients with hematologic malignancies.
Ueda T; Matsuyama S; Yamauchi T; Kishi S; Fukushima T; Tsutani H; Nakamura T; Gotoh N; Masada M
Adv Exp Med Biol; 1998; 431():647-51. PubMed ID: 9598145
[No Abstract] [Full Text] [Related]
3. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.
Parmar S; Seeringer A; Denich D; Gärtner F; Pitterle K; Syrovets T; Ohmle B; Stingl JC
Pharmacogenomics; 2011 Apr; 12(4):503-14. PubMed ID: 21521023
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.
Esteva FJ; Soh LT; Holmes FA; Plunkett W; Meyers CA; Forman AD; Hortobagyi GN
Cancer Chemother Pharmacol; 2000; 46(5):382-6. PubMed ID: 11127942
[TBL] [Abstract][Full Text] [Related]
5. Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure.
Radeski D; Cull GM; Cain M; Hackett LP; Ilett KF
Cancer Chemother Pharmacol; 2011 Apr; 67(4):765-8. PubMed ID: 20532508
[TBL] [Abstract][Full Text] [Related]
6. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma.
Qi N; Cai C; Zhang W; Niu Y; Yang J; Wang L; Tian B; Liu X; Lin X; Zhang Y; Zhang Y; He H; Chen K; Tang X
Int J Pharm; 2014 Sep; 472(1-2):48-55. PubMed ID: 24914829
[TBL] [Abstract][Full Text] [Related]
7. In-vitro transdermal penetration of cytarabine and its N4-alkylamide derivatives.
Legoabe LJ; Breytenbach JC; N'Da DD; Breytenbach JW
J Pharm Pharmacol; 2010 Jun; 62(6):756-61. PubMed ID: 20636863
[TBL] [Abstract][Full Text] [Related]
8. A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors.
Liu R; Jiang Y; Hu X; Wu J; Jiang W; Jin G; Luan Y
Int J Pharm; 2018 Dec; 552(1-2):111-118. PubMed ID: 30268848
[TBL] [Abstract][Full Text] [Related]
9. [Petechiae, suffusions and cytarabine-induced erythema in treatment of acute myeloid leukemia].
Taverna C; Jacky E; Sauter C
Schweiz Med Wochenschr; 1998 Jul; 128(27-28):1117. PubMed ID: 9691347
[No Abstract] [Full Text] [Related]
10. Comparison of leukopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group.
Miyawaki S; Kobayashi T; Tanimoto M; Kuriyama K; Murakami H; Yoshida M; Minami S; Minato K; Tsubaki K; Omoto E; Oh H; Jinnai I; Sakamaki H; Hiraoka A; Kanamaru A; Takahashi I; Saito K; Naoe T; Yamada O; Asou N; Kageyama S; Emi N; Ueda T; Tomonaga M; Ohno R
Int J Hematol; 1999 Jul; 70(1):56-7. PubMed ID: 10446497
[No Abstract] [Full Text] [Related]
11. Cerebellar toxicity due to cytarabine: A series of 4 cases.
Sainz de la Maza Cantero S; Jiménez Martín A; de Felipe Mimbrera A; Corral Corral Í
Neurologia; 2016 Sep; 31(7):491-2. PubMed ID: 25728956
[No Abstract] [Full Text] [Related]
12. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
13. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
Seymour JF; Huang P; Plunkett W; Gandhi V
Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
[TBL] [Abstract][Full Text] [Related]
14. [The pharmacokinetic study on cytarabine nanoparticle lyophilization injection in rabbits].
Zhou J; Jiang XH; He L; Li CR; Yang JY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):145-7. PubMed ID: 16468665
[TBL] [Abstract][Full Text] [Related]
15. Cytarabine-induced neurotoxicity responding to methyl prednisolone.
Malhotra P; Mahi S; Lal V; Kumari S; Jain S; Varma S
Am J Hematol; 2004 Dec; 77(4):416. PubMed ID: 15551283
[No Abstract] [Full Text] [Related]
16. Cytarabine ears - A side effect of cytarabine therapy.
Doval D; Kumar Sharma S; Kumar M; Khandelwal V; Choudhary D
J Oncol Pharm Pract; 2020 Mar; 26(2):471-473. PubMed ID: 31117913
[TBL] [Abstract][Full Text] [Related]
17. Resident rounds. Part III: Neutrophilic eccrine hidradenitis in the setting of acute myelogenous leukemia treated with cytarabine.
Shlapak D; Kerisit K; Lin C; Wang A; Stumpf B
J Drugs Dermatol; 2013 Feb; 12(2):231-2. PubMed ID: 23550319
[No Abstract] [Full Text] [Related]
18. Cytarabine therapy for refractory cutaneous lupus.
Yung RL; Richardson BC
Arthritis Rheum; 1995 Sep; 38(9):1341-3. PubMed ID: 7575733
[No Abstract] [Full Text] [Related]
19. What does over-expression of cN-II enzyme signify in haematological malignancies?
Galmarini CM
Leuk Res; 2007 Oct; 31(10):1325-6. PubMed ID: 17434583
[No Abstract] [Full Text] [Related]
20. Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
Liang A; Zhang H; Fang Y; Li Y; Zhu D; Chen F; Lu H; Fu J; Bo L
Pharmazie; 2012 Jul; 67(7):635-8. PubMed ID: 22888522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
